CEPHADOL Safety Questions, CEPHADOL Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about CEPHADOL. Our extensive database of CEPHADOL adverse events and CEPHADOL warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about CEPHADOL
CEPHADOL Safety Reports
Total CEPHADOL reports: 4.CEPHADOL FDA safety alerts: No.
Reported deaths: 4 Reported hospitalizations: 4.
Take CEPHADOL Side Effects Survey or Share Your CEPHADOL Story. Read More Here.
Consumer or non-health professional from JAPAN reported CEPHADOL problem on Mar 28, 2007. Female patient, 66 years of age, weighting 119.0 lb, was diagnosed with dizziness, hyperuricaemia, nausea, chronic myeloid leukaemia and was treated with CEPHADOL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood creatine phosphokinase increased, blood creatinine increased, blood pressure decreased, blood urea increased, c-reactive protein increased, dehydration. CEPHADOL dosage: unknown. During the same period patient was treated with URALYT, ALLOPURINOL, NOVAMIN, TICLOPIDINE, MERISLON, GLEEVEC. Patient was hospitalized. Patient died.
CEPHADOL problem was reported by a Physician from JAPAN on Oct 11, 2006. Female patient, 66 years of age, was diagnosed with dizziness, hyperuricaemia, nausea, chronic myeloid leukaemia and was treated with CEPHADOL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood creatine phosphokinase increased, blood creatinine increased, blood pressure decreased, blood urea increased, c-reactive protein increased, dehydration. CEPHADOL dosage: unknown. During the same period patient was treated with URALYT, ALLOPURINOL, NOVAMIN, PANALDINE, MERISLON, GLEEVEC. Patient was hospitalized. Patient died.
Consumer or non-health professional from JAPAN reported CEPHADOL problem on July 11, 2007. Female patient, 66 years of age, weighting 119.0 lb, was diagnosed with dizziness, hyperuricaemia, nausea, chronic myeloid leukaemia and was treated with CEPHADOL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood creatine phosphokinase increased, blood creatinine increased, blood pressure decreased, blood urea increased, c-reactive protein increased, dehydration. CEPHADOL dosage: unknown. During the same period patient was treated with URALYT, ALLOPURINOL, NOVAMIN, TICLOPIDINE, MERISLON, GLEEVEC. Patient was hospitalized. Patient died.
CEPHADOL problem was reported by a Consumer or non-health professional from JAPAN on July 19, 2007. Female patient, 66 years of age, weighting 119.0 lb, was diagnosed with dizziness, hyperuricaemia, nausea, chronic myeloid leukaemia and was treated with CEPHADOL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood creatine phosphokinase increased, blood creatinine increased, blood pressure decreased, blood urea increased, c-reactive protein increased, dehydration. CEPHADOL dosage: unknown. During the same period patient was treated with URALYT, ALLOPURINOL, NOVAMIN, TICLOPIDINE, MERISLON, GLEEVEC. Patient was hospitalized. Patient died on 10/10/2006.